Last updated 12 days ago
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
14550 patients around the world
Available in United States, Argentina
Merck Sharp & Dohme LLC
63Research sites
14550Patients around the world
This study is for people with
Hypercholesterolemia
Cardiovascular disease
Established cardiovascular disease
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
CIPREC Centro de Investigación y Prevención Cardiovascular - CABA
Recruiting
CEDIMBA - DIM Clínica Privada - Buenos Aires
Recruiting
Instituto Médico Damic S.R.L.
Recruiting
Centro de Investigaciones Metabólicas (CINME) S.A. - CABA, Buenos Aires
Recruiting
Instituto de Investigaciones Clínicas Mar del Plata
Recruiting
Clínica de Nefrología Urología y Enfermedades Cardiovasculares - Santa Fe
Recruiting
Centro Medico Dra. Laura Maffei - Investigación Clínica Aplicada
Recruiting
Instituto Médico de la Fundación Estudios Clínicos - Rosario
Recruiting
CEDIC Centro de Investigación Clínica - CABA, Buenos Aires
Recruiting
Fundación Respirar
Recruiting
StudyCORALreef Outcomes - MK-0616-015
SponsorMerck Sharp & Dohme LLC
Conditions
HypercholesterolemiaEstablished cardiovascular disease
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06008756
